Page last updated: 2024-11-13

gsk2245035

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GSK2245035: a Toll-like receptor 7 agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44623937
CHEMBL ID4297492
SCHEMBL ID565847
MeSH IDM000612681

Synonyms (23)

Synonym
SCHEMBL565847
6-amino-2-{[(1s)-1-methylbutyl]oxy}-9[5-(1-piperidinyl) pentyl]-7,9-dihydro-8h-purin-8-one
6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one
LFMPVTVPXHNXOT-HNNXBMFYSA-N
6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl) pentyl]-7,9-dihydro-8h-purin-8-one
6-amino-2-[(2s)-pentan-2-yloxy]-9-[5-(piperidin-1-yl)pentyl]-8,9-dihydro-7h-purin-8-one
gtpl9254
gsk2245035
compound 32 [pmid: 26861551]
gsk-2245035
unii-5l3sx16qbq
5L3SX16QBQ ,
8h-purin-8-one, 6-amino-7,9-dihydro-2-((1s)-1-methylbutoxy)-9-(5-(1-piperidinyl)pentyl)-
1207629-49-9
AKOS032954203
CS-0065520
HY-118250
6-amino-2-[(2s)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7h-purin-8-one
F3409-0744
(s)-6-amino-2-(pentan-2-yloxy)-9-(5-(piperidin-1-yl)pentyl)-7,9-dihydro-8h-purin-8-one
CHEMBL4297492
MS-26512
6-amino-7,9-dihydro-2-[(1s)-1-methylbutoxy]-9-[5-(1-piperidinyl)pentyl]-8h-purin-8-one

Research Excerpts

Overview

GSK2245035 is a novel selective TLR7 agonist in pharmaceutical development.

ExcerptReferenceRelevance
"GSK2245035 is a novel selective TLR7 agonist in pharmaceutical development."( Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial.
Ellis, AK; Lee, LA; Powley, W; Quint, D; Tsitoura, DC, 2017
)
1.44

Toxicity

ExcerptReferenceRelevance
" Adverse events (AEs) including cytokine release syndrome AEs (CytoRS-AEs) and nasal symptoms were assessed."( Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial.
Ellis, AK; Lee, LA; Powley, W; Quint, D; Tsitoura, DC, 2017
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Target engagement was confirmed in humans following single intranasal doses of 32 of ≥20 ng, and reproducible pharmacological response was demonstrated following repeat intranasal dosing at weekly intervals."( Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma.
Ahmed, M; Ball, DI; Biggadike, K; Coe, DM; Dalmas Wilk, DA; Edwards, CD; Gibbon, BH; Hardy, CJ; Hermitage, SA; Hessey, JO; Hillegas, AE; Hughes, SC; Lazarides, L; Lewell, XQ; Lucas, A; Mallett, DN; Price, MA; Priest, FM; Quint, DJ; Shah, P; Sitaram, A; Smith, SA; Stocker, R; Trivedi, NA; Tsitoura, DC; Weller, V, 2016
)
0.65
" Potentially, lower IFN-α and IP-10 levels as well as once-weekly intranasal dosing vs daily subcutaneous or intramuscular dosing with recombinant type I IFNs could explain the lack of pregnancy effects; however, there was an undesired impact on offspring immune function."( GSK2245035, a TLR7 agonist, Does Not Increase Pregnancy Loss in Cynomolgus Monkeys.
Baker, A; Bray, M; Hillegas, AE; Maier, CC; Phadnis-Moghe, AS; Posobiec, LM; Price, MA; Stanislaus, DJ, 2021
)
2.06
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1345471Human TLR7 (Toll-like receptor family)2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.57 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (60.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other2 (40.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]